FLUOXETINE-TEVA 20 MG CAPSULES

Krajina: Singapur

Jazyk: angličtina

Zdroj: HSA (Health Sciences Authority)

Aktívna zložka:

FLUOXETINE ( as HCl)

Dostupné z:

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

ATC kód:

N06AB03

Dávkovanie:

20 mg

Forma lieku:

CAPSULE

Zloženie:

FLUOXETINE ( as HCl) 20 mg

Spôsob podávania:

ORAL

Typ predpisu:

Prescription Only

Výrobca:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Stav Autorizácia:

ACTIVE

Dátum Autorizácia:

2003-06-05

Príbalový leták

AAAO2168 - FLUOXETINE 20 MG, PIL, SINGAPORE
02
4.05.2022
InA
18.05.2022
InA
160x560 mm
Teva Israel
8 pt
Black
FLUOXETINE-TEVA 20 MG CAPSULES
COMPOSITION
Each capsule contains: Active Ingredient
Fluoxetine (as hydrochloride) 20 mg
_Other Ingredients:_
Simethicone emulsion, colloidal silicon dioxide, pregelatinized
starch.
MECHANISM OF ACTION
Fluoxetine is an antidepressant which is chemically unrelated to
tetracyclic or other available antidepressant agents. The mechanism
of action of fluoxetine is complex and in some ways resembles
that of other antidepressant agents, particularly those agents
(e.g., clomipramine, trazodone) that predominantly potentiate the
pharmacologic effects of serotonin. Unlike other currently available
serotonin-enhancing antidepressant agents, fluoxetine is a highly
selective reuptake inhibitor of serotonin and has little or no effect
on
other neurotransmitters.
_PHARMACODYNAMICS_
_Central Nervous System Effects_
The precise mechanism of antidepressant action of fluoxetine is
unclear, but the drug has been shown to selectively inhibit the
reuptake of serotonin (5-HT) at the presynaptic neuronal membrane.
Fluoxetine- induced inhibition of serotonin reuptake causes increased
synaptic concentrations of serotonin in the CNS, resulting in
numerous functional changes associated with enhanced serotonergic
neurotransmission. Unlike most other current available antidepressant
agents, fluoxetine appears to have minimal or no effect on the
reuptake of norepinephrine or dopamine and does not exhibit clinically
important anticholinergic, antihistaminic, or (alpha)1- adrenergic
blocking activity at usual therapeutic dosages.
_Cardiovascular Effects_
The cardiovascular effects of fluoxetine have been studied in animals
and to a limited extent in humans. Unlike most other antidepressant
agents (e.g., tricyclic antidepressants, MAO inhibitors), fluoxetine
has been associated with only minimal cardiovascular effects. The
absence of substantial activity, (alpha)1-adrenergic blocking
activity,
catecholamine-